Back to Search
Start Over
Significantly altered peripheral blood cell DNA methylation profile as a result of immediate effect of metformin use in healthy individuals
- Source :
- Clinical Epigenetics, Vol 10, Iss 1, Pp 1-13 (2018), Clinical Epigenetics
-
Abstract
- Background Metformin is a widely prescribed antihyperglycemic agent that has been also associated with multiple therapeutic effects in various diseases, including several types of malignancies. There is growing evidence regarding the contribution of the epigenetic mechanisms in reaching metformin’s therapeutic goals; however, the effect of metformin on human cells in vivo is not comprehensively studied. The aim of our study was to examine metformin-induced alterations of DNA methylation profiles in white blood cells of healthy volunteers, employing a longitudinal study design. Results Twelve healthy metformin-naïve individuals where enrolled in the study. Genome-wide DNA methylation pattern was estimated at baseline, 10 h and 7 days after the start of metformin administration. The whole-genome DNA methylation analysis in total revealed 125 differentially methylated CpGs, of which 11 CpGs and their associated genes with the most consistent changes in the DNA methylation profile were selected: POFUT2, CAMKK1, EML3, KIAA1614, UPF1, MUC4, LOC727982, SIX3, ADAM8, SNORD12B, VPS8, and several differentially methylated regions as novel potential epigenetic targets of metformin. The main functions of the majority of top-ranked differentially methylated loci and their representative cell signaling pathways were linked to the well-known metformin therapy targets: regulatory processes of energy homeostasis, inflammatory responses, tumorigenesis, and neurodegenerative diseases. Conclusions Here we demonstrate for the first time the immediate effect of short-term metformin administration at therapeutic doses on epigenetic regulation in human white blood cells. These findings suggest the DNA methylation process as one of the mechanisms involved in the action of metformin, thereby revealing novel targets and directions of the molecular mechanisms underlying the various beneficial effects of metformin. Trial registration EU Clinical Trials Register, 2016-001092-74. Registered 23 March 2017, https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001092-74/LV. Electronic supplementary material The online version of this article (10.1186/s13148-018-0593-x) contains supplementary material, which is available to authorized users.
- Subjects :
- Adult
Male
0301 basic medicine
lcsh:QH426-470
endocrine system diseases
lcsh:Medicine
Pharmacology
medicine.disease_cause
Epigenesis, Genetic
Pharmaceutical Sciences
03 medical and health sciences
Genetics
Humans
Medicine
Gene Regulatory Networks
Peripheral blood cell
Longitudinal Studies
Epigenetics
Pharmaceutical sciences
Molecular Biology
Genetics (clinical)
Blood Cells
DNA methylation
Whole Genome Sequencing
business.industry
Research
lcsh:R
Farmaceutiska vetenskaper
Healthy Volunteers
Metformin
Human genetics
3. Good health
lcsh:Genetics
030104 developmental biology
Differentially methylated regions
White blood cells
CpG Islands
Female
Longitudinal study
business
Carcinogenesis
Developmental Biology
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 18687083 and 18687075
- Volume :
- 10
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Clinical Epigenetics
- Accession number :
- edsair.doi.dedup.....8b5fc0a44f085b8155e30a9f206ae210
- Full Text :
- https://doi.org/10.1186/s13148-018-0593-x